While cyclin-dependent kinase (CDK)4/6 inhibitors have become a mainstay of treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2–) metastatic breast cancer (mBC), many patients still receive first-line treatment with chemotherapy, even in the absence of visceral crisis. Lacking head-to-head clinical trials comparing treatment approaches, a recent meta-analysis compared results from phase II and III […]

MorphoSys AG announced the combination of the CD19-targeted antibody tafasitamab with lenalidomide resulted in a statistically significant improvement in best objective response rate (ORR) compared with a real-world data-matched control cohort of lenalidomide alone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This announcement was based on results from the retrospective observational matched-control cohort […]

According to a recent study conducted by Memorial Sloan Kettering Cancer Center, rates of Clostridioides difficile infection (CDI) are higher in patients with cancer than in healthy adults. This study used patient data from 93,566 patients in the SEER-Medicare database, including both healthy patients and patients with either solid tumors or hematologic malignancies diagnosed between […]

Although clinicians and drug manufacturers have always touted the value of certain treatments, cost-effectiveness hasn’t always been an integral part of the pharma market. However, priorities have shifted in recent years and value-based pricing has begun to dominate the US pharma market. As market access shifts, pharma companies must change their business model or risk […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and positively impact patient care. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices, along with leading scientific experts, gather […]

Guidelines from the National Comprehensive Cancer Network (NCCN) provide the foundation for treatment of breast cancer in the United States. However, as many as 1 in 5 patients receive treatment regimens that are not recommended by the NCCN, according to a recent study published in the Journal of the National Comprehensive Cancer Network. In this […]